Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest QIAGEN N.V. Stories

2014-04-16 08:30:31

GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- -- Investment of $10 million in Germantown and Frederick campuses brings QIAGEN's total recent commitment in Maryland to $50 million -- Germantown campus becomes state-of-the-art research, manufacturing and office site for Molecular Diagnostics with consolidation of activities from Gaithersburg site -- Germantown site passes FDA pre-approval inspection to manufacture digene HC2 HPV Test --...

2014-04-10 16:24:24

HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the New England Journal of...

2014-04-03 04:20:47

SAN DIEGO and HILDEN, Germany, April 3, 2014 /PRNewswire/ -- - New innovative product launches at American Association for Cancer Research (AACR) Annual Meeting add to broad portfolio of NGS solutions - High-speed QIAxpert accelerates quantification and quality control of nucleic acids with easy-to-use software and analysis aiding sample-to-insight workflows - CLC Cancer Research Workbench is the world's first...

2014-03-20 04:21:53

BEIJING and HILDEN, Germany, March 20, 2014 /PRNewswire/ -- - QuantiFERON-TB, the leading modern test for accurate diagnosis of latent tuberculosis infections, continues to grow rapidly around the world - Commercial launch of QuantiFERON-TB in China, where latent TB affects an estimated 41% of population, will support nationwide efforts to control TB - QIAGEN marks World TB Day 2014 on March 24 with QuantiFERON-TB...

2014-03-12 20:24:37

HILDEN, Germany, March 12, 2014 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today the successful completion of the following series of transactions: - The repurchase from non-U.S. holders of approximately $291 million(1) notional amount of its outstanding convertible notes due 2026 (the "2026 Notes"); - In order to finance the repurchase, and also raise $300 million of net proceeds, the...

2014-03-12 20:24:32

HILDEN, Germany, March 12, 2014 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today the successful completion of the following series of transactions: - The repurchase from non-U.S. holders of approximately $291 million(1) notional amount of its outstanding convertible notes due 2026 (the "2026 Notes"); - In order to finance the repurchase, and also raise $300 million of net proceeds, the...

2014-03-12 12:29:22

HILDEN, Germany, March 12, 2014 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today the terms of the new senior unsecured cash settled convertible notes (the "Notes"). The size of the offering will be approximately $430 million aggregate principal amount of convertible notes due 2019 (the "2019 Notes") and $300 million aggregate principal amount of convertible notes due 2021 (the "2021 Notes"). The 2019 Notes will bear interest at...

2014-03-11 04:21:07

HILDEN, Germany and GERMANTOWN, Maryland, March 11, 2014 /PRNewswire/ -- - GeneGlobe web portal now powered by QIAGEN's Ingenuity Target Explorer, linking assay search and selection tools with curated biological context - Enhanced search results save time and help scientists design cost-effective studies - GeneGlobe portal provides access to more than 31 million PCR and NGS assay options available through QIAGEN,...

2014-02-26 04:21:32

KOLKATA, India, February 26, 2014 /PRNewswire/ -- - The careHPV(TM) Test is the first HPV diagnostic designed for regions with limited healthcare infrastructure, complementing QIAGEN's market-leading digene HC2 HPV Test - Commercial launch of careHPV Test in India enables high-quality screening for prevention of cervical cancer among women in low-resource areas - The careHPV Test plays an important role in QIAGEN's...

2014-02-12 04:20:52

MARCO ISLAND, Florida and HILDEN, Germany, February 12, 2014 /PRNewswire/ -- - Significant expansion of 'universal' portfolio compatible with any NGS system includes several novel sample preparation products as well as solutions for clinical use - New bioinformatics solutions, including CLC Cancer Research Workbench and Ingenuity Clinical will accelerate analysis and interpretation of NGS data QIAGEN N.V. (NASDAQ:...